Amgen Intends To Engage With FDA, Continues To Believe Tavneos Demonstrates Effectiveness & Favorable Benefit–Risk Profile; On April 29, Submitted A Changes Being Effected Supplement To FDA For Tavneos; CBE-30 Filing Amends Hepatotoxicity Warning Language In Label To Provide More Information On Cases Of VBDS Related To Tavneos